Aktionärsstruktur

Inhaber in %
Freefloat 99.90
Vanguard Group, Inc. (Subfiler) 8.38
The Vanguard Group, Inc. 8.29
State Street Corp. 5.12
SSgA Funds Management, Inc. 4.99
Capital Research & Management Co. (World Investors) 4.43
Wellington Management Co. LLP 3.76
Vanguard Total Stock Market Index Fund 3.00
BlackRock Fund Advisors 2.94
Vanguard 500 Index Fund 2.29
BlackRock Institutional Trust Co. NA 2.16
Geode Capital Management LLC 1.97
Charles Schwab Investment Management, Inc. 1.25
Northern Trust Corp. 1.19
Washington Mutual Investors Fund 1.12

*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.

Personal

2017 2018 2019 2020 2021
Personal am Ende des Jahres 90'200 92'400 88'300 78'500 79'000
Umsatz pro Mitarbeiter in Mio. EUR 0.58 0.58 0.59 0.53 1.03

Bilanz (in Mio. EUR) - Aktiva

2017 2018 2019 2020 2021
Summe Umlaufvermögen 41'141 49'926 32'803 35'067 59'693
Summe Anlagevermögen 114'799 105'147 116'616 104'509 118'596
Summe Aktiva 171'797 159'422 167'489 154'229 181'476

Bilanz (in Mio. EUR) - Passiva

2017 2018 2019 2020 2021
Gesamtverschuldung/ -verbindlichkeiten 43'491 41'740 53'474 41'271 41'395
Summe Fremdkapital 100'141 95'664 104'044 90'756 104'013
Summe Eigenkapital 71'656 63'758 63'445 63'473 77'463
Summe Passiva 171'797 159'422 167'489 154'229 181'476

Adresse

235 East 42nd Street, 10017-5755 New York
Telefon +1 (212) 733-2323
URL http://www.pfizer.com

Management

Aamir Malik
Chief Business Innovation Officer & Executive VP
Aida Habtezion
Chief Medical Officer
Albert Bourla
Chairman, Chief Executive & Operating Officer
Andy Schmeltz
Senior VP-Commercial Strategy & Innovation
Angela Hwang
Group President-Biopharmaceuticals
Annaliesa Anderson
VP, Head-Vaccine Research & Development
Barbara J. Dalton
Vice President-Worldwide Business Development
Brenda Cooperstone
Chief Development Officer & Senior Vice President
Bryan Dunn
Investor Relations Contact
Christopher J. Stevo
Senior Vice President
Dan R. Littman
Independent Director
David DeMicco
Head-Medical Affairs, Global Innovative Products
David M. Denton
Chief Financial Officer & Executive Vice President
Deborah Baron
Senior VP-Worldwide Business Development
Denis Patrick
Executive Director
Donna Wartski
Dir-Med Outcomes Specialist, US Medical Affairs
Douglas M. Lankler
Executive Vice President & General Counsel
Eva Grut-Aandahl
Vice President, Head of EU Government Affairs
Gordon Loh
Senior Vice President-Corporate Audit
Hakan Sakul
Vice President & Head-Diagnostics
Helen H. Hobbs
Independent Director
James C. Smith
Independent Director
James Quincey
Independent Director
Jennifer B. Damico
Senior VP-Controller & Accounting Officer
John DeYoung
Vice President-Worldwide Business Development
Joseph J. Echevarria
Independent Director
Lidia L. Fonseca
Executive VP, Chief Digital & Technology Officer
Margaret M. Madden
Secretary, Chief Governance Counsel & Senior VP
Markus Green
Vice President & Assistant General Counsel
Mikael Dolsten
Chief Scientific Officer & Research President
Mike McDermott
Chief Global Supply Officer & Executive VP
Payal Sahni Becher
Chief Human Resources Officer & Executive VP
Rady A. Johnson
Executive VP, Chief Compliance & Risk Officer
Ronald E. Blaylock
Independent Director
Sally Susman
Chief Corporate Affairs Officer & Executive VP
Scott Gottlieb
Member of the Board of Directors
Shantanu Narayen
Lead Independent Director
Suneet Varma
President-US Oncology Business Unit
Susan D. Desmond-Hellmann
Director
Susan J. Hockfield
Independent Director
Suzanne Nora Johnson
Independent Director
William Pao
Chief Development Officer & Executive VP

Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen
Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.